In Vitro susceptibilities of wild and drug resistant Leishmania donovani amastigote stages to andrographolide nanoparticle: Role of vitamin e derivative TPGS for nanoparticle efficacy

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Mondal, Subhasish ^a   Roy, Partha ^b   Das, Suvadra ^b   Halder, Asim ^b   Mukherjee, Arup ^b   Bera, Tanmoy ^a  

^a JADAVPUR UNIVERSITY   (India)

^b UNIVERSITY OF CALCUTTA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; AMPHOTERICIN B; ANDROGRAPHOLIDE; MACROGOL 10000; NANOPARTICLE; PAROMOMYCIN; STIBOGLUCONATE SODIUM; ALPHA TOCOPHEROL; ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; DITERPENE; LACTIC ACID; MACROGOL DERIVATIVE; MICROCAPSULE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

AMASTIGOTE; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; DISPERSION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; ENCAPSULATION; EVAPORATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTERNALIZATION; LEISHMANIA DONOVANI; MALE; MOUSE; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PERITONEUM MACROPHAGE; PHOTON CORRELATION SPECTROSCOPY; SOLVENT EXTRACTION; SUSTAINED DRUG RELEASE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG INTERACTION; DRUG RESISTANCE; DRUG STABILITY; GROWTH, DEVELOPMENT AND AGING; KINETICS; METABOLISM; MICROCAPSULE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; CAPSULES; DITERPENES; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG STABILITY; FEMALE; KINETICS; LACTIC ACID; LEISHMANIA DONOVANI; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; VITAMIN E;

EID: 84892382267     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081492     Document Type: Article

References (43)

1. Niranjan A, Tewari SK, Lehri A (2010) Biological activities of Kalmegh (Andrographis paniculata Nees) and its active principles- A review. Ind J Natural Products Resource 1: 125-135.
2. Misra P, Pal NL, Guru PY, Katiyar JC, Srivastava V, et al. (1992) Antimalarial Activity of Andrographis paniculata (Kalmegh) against Plasmodium berghei NK 65 in Mastomys natalensis. Pharm Biol 30: 263-274.
3. Sinha J, Mukhopadhyay S, Das N, Basu MK (2000) Targeting of liposomal andrographolide to L. donovani -infected macrophages in vivo. Drug Deliv 7: 209-213.
4. Lala S, Nandy AK, Mahato SB, Basu MK (2003) Delivery in vivo of 14-deoxy-11oxoandrographolide, an antileishmanial agent, by different drug carriers. Indian J Biochem Biophys 40: 169-174.
5. 3-andrographolide by autoradiography. Acta Pharmacologica Sinica 2: 266-269.
6. Zhang Z, Songwei Tan S, Feng SS (2012) Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 33: 4889-4906.
7. Win KY, Feng SS (2005) Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26: 2713-2722.
8. Zhang ZP, Lee SH, Gan CW, Feng SS (2008) In vitro and in vivo investigation on PLATPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm Res 25: 1925-1935.
9. Zhang ZP, Feng SS (2006) Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release. Biomaterials 27: 262-270.
10. Denton H, Mc Gregor JC, Coombs GH (2004) Reduction of antileishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem J 381: 405-412.
11. Zhou Y, Messier N, Quellette M, Rosen BP, Mukhopadhyay R (2004) Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug Pentostam. J Biol Chem 279: 37445-37451.
12. Santos Ferreira C, Martins PS, Demicheli C, Brochu C, Ouellette M, et al. (2003) Thiol-induced reduction of antimony (V) into antimony (III) : a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals 16: 441-446.
13. Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mondal D, et al. (2011) Characterization of antimony-resistant Leishmania donovani isolates : Biochemical and biophysical studies and interaction with host cells. Int J Parasitol 41: 1311-1321.
14. Garcia-Hernander R, Manzano SI, Castanys S, Gamarro F (2012) Leishmania donovani develops resistance to drug combinations. Plos Negl Trop Dis 6: e 1974.
15. Cortes-Selva F, Munoz-Martenez F, Illias A, Jimenez AI, Varadi A, et al (2005) Functional expression of a multidrug P-glycoprotein transporter of Leishmania. Biochem Biophys Res Commun 329: 502-507.
16. Stand F, Ceckova M, Micuda S, Pavek P (2010) Expression and function of Pglycoprotein in normal tissues : effect on pharmacokinetics. Methods Mol Biol 596: 199-222.
17. Werle M (2008) Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res 25: 500-511.
18. Roy P, Das S, Bera T, Mondol S, Mukherjee A (2010) Andrographolide nanoparticles in leishmaniasis: characterization and in vitro evaluations. Int J Nanomed 5: 1113-1121.
19. Roy P, Das S, Auddy RG, Saha A, Mukherjee A (2013) Engineered andrographolide nanoparticles mitigate paracetamol hepatotoxicity in mice. Pharm Res 30: 1252-1262.
20. Biyani N, Singh AK, Mandal S, Chawla B, Madhubala R (2011) Differential expression of proteins in antimony-susceptible and resistant isolates of Leishmania donovani. Mol Biochem Parasitol 179: 91-99.
21. Maharjan M, Singh S, Chatterjee M, Madhubala R (2008) Role of aquaglyceroprorin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani. Am J Trop Med Hyg 79: 69-75.
22. Mondal S, Maharjan S, Singh S, Chatterjee M, Madhubala R (2010) Assesing aquaglyceroporin gene status and expression profile in antimony-susceptible and resistant clinical isolates of Leishmania donovani from India. J Antimicrob Chemother 65: 496-507.
23. Mukherjee A, Padmanabhan PK, Singh S, Roy G, Girard I, et al. (2007) Role of ABC transporter MRPA, gamma 454 glutamylcystiene synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani. J Antimicrob Chemother 59: 204-211.
24. Basu JM, Mukherjee A, Banerjee R, Saha M, Singh S, et al. (2008) Inhibition of ABC transporters abolishes antimony resistance in Leishmania infection. Antimicrob Agents Chemother 52: 1080-1093.
25. Iovannisci DM, Ullman B (1983) High efficiency plating method for Leishmania promastigotes in semi-defined or completely-defined media. J Parasitol 69: 633-636.
26. Kar K, Mukherjee K, Naskar K, Bhattacharya A, Ghosh DK (1990) Leishmania donovani : a chemically defined medium suitable for cultivation and cloning of promastigotes and transformation of amastigotes to promastigotes. J Protozool 37: 277-279.
27. Das S, Roy P, Mondal S, Bera T, Mukherjee A (2013) One pot synthesis of gold nanoparticles and application in chemotherapy of wild and resistant type visceral leishmaniasis. Colloids Surfaces B: Biointerfaces 107: 27-34.
28. Debrabant A, Joshi MB, Pimenta PF, Dwyer D (2004) Generation of Leishmania donovani axenic amastigotes : their growth and biological characteristics. Int J Parasitol 34: 205-217.
29. Senero D, Lemers JL (1997) Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents. Antimicrob Agents Chemother 41: 972-976.
30. 50 in studies of drug resistance of malaria parasites. Acta Trop 55: 257-261.
31. Nwaka S, Hudson A (2005) Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov 5: 941-955.
32. Budhian A, Siegel SJ, Winey KI (2007) Haloperidol-loaded PLGA nanoparticles: Systemic study of particle size and drug content. Int J Pharm 336: 367-375.
33. Lu Z, Bei JZ, Wang SG (1999) A method for the preparation of polymeric nanocapsules without stabilizer, J Control Release 61: 107-112.
34. Jalali N, Moztarzadeha F, Mozafaria M, Asgarib S, Motevalian M, et al. (2011) Surface modification of poly (lactide-co-glycolide) nanoparticles by d-α-tocopheryl polyethylene glycol 1000 succinate as potential carrier for the delivery of drugs to the brain. Colloids and Surfaces A: Physicochem. Eng Aspects 392: 335-342.
35. Xu A, Yao M, Xu G, Ying J, Ma W, et al. (2012) A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants. Int J Nanomed 7: 3547-3554.
36. Korsemeyer RW, Gurny R, Doelker EM, Buri P, Peppas NA (1983) Mechanism of solute release from porous hydrophilic polymers. Int J Pharm 15: 25-35.
37. Grattard N, Pernin M, Marty B, Roudaut G, Champion D, et al. (2002) Study of release kinetics of small and high molecular weight substances dispersed into spray-dried ethylcellulose microspheres. J Control Rel 84: 125-135.
38. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL : the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37: 1590-1598.
39. Collnot EM, Baldes C, Wempe MF, Hyatt J, Navarro L, et al. (2006) Influence of vitamin E TPGS poly(ethylene glycol) chain lenth on apical efflux transporters in Caco-2 cell monolayers. J Control Release 111: 35-40.
40. Collnot EM, Baldes C, Wempe MF, Kappel R, Hiittermann J, et al (2007) Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS : influence on ATPase activity and membrane fluidity. Mol Pharm 4: 465-474.
41. Vasir JK, Reddy MK, Labhasetwar VD (2005) Nanosystems in drug targeting: Opportunities and challenges. Curr Nanosci 1: 47-64.
42. Croft SL, Coombs GH (2003) Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19: 502-508.
43. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM (2008) Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 125: 193-209.